FMC: 'We looked at the omega-3 area broadly and it was clear Epax was the premier property in this space'
While the $345m acquisition of omega-3 firm Epax will keep it busy for a while, FMC Corporation is still on the lookout for other deals in other high-growth areas of the nutraceuticals market, says the man in charge of its fast-growing health and...